| U.S. Brand Names |
| Albalon-A® Ophthalmic; Antazoline-V® Ophthalmic; Vasocon-A®[OTC] Ophthalmic |
 |
| Generic Available |
|
No |
|
| Pharmacological Index |
|
Ophthalmic Agent, Vasoconstrictor |
|
| Use |
|
Topical ocular congestion, irritation and itching |
|
| Pregnancy Risk Factor |
|
C |
|
| Contraindications |
|
Angle-closure glaucoma; hypersensitivity to naphazoline or antazoline |
|
| Adverse Reactions |
|
1% to 10%: Central nervous system: Nervousness, dizziness, headache Gastrointestinal: Nausea Local: Transient stinging Neuromuscular & skeletal: Weakness Ocular: Mydriasis, increased intraocular pressure, blurring of vision Respiratory: Nasal mucosa irritation, dryness, rebound congestion Miscellaneous: Diaphoresis |
|
| Drug Interactions |
|
MAO inhibitors |
|
| Stability |
|
Store in tight, light-resistant containers |
|
| Usual Dosage |
|
1-2 drops every 3-4 hours |
|
| Mental Health: Effects on Mental Status |
|
May cause nervousness or dizziness |
|
| Mental Health: Effects on Psychiatric Treatment |
|
TCAs and MAOIs may potentiate the pressor response of decongestants; monitor for changes in response |
|
| Dental Health: Local Anesthetic/Vasoconstrictor Precautions |
|
No information available to require special precautions |
|
| Dental Health: Effects on Dental Treatment |
|
No effects or complications reported |
|
| Patient Information |
|
Do not use discolored solutions |
|
| Nursing Implications |
|
Do not use discolored solutions |
|
| Dosage Forms |
|
Solution: Naphazoline hydrochloride 0.05% and antazoline phosphate 0.5% (15 mL) |
|
|
Copyright © 2007 Drugs Area |
